Clinical Trials Browser

Phase 2 × Has results × rasburicase × Clear all

Leukemia, Lymphoma, Tumor Lysis Syndrome, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT01564277 2018-01-09

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Congenital Abnormalities, Blast Crisis, Burkitt Lymphoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00057811 2014-09-19

Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

Phase 2 Completed

97 enrolled 13 charts

LymphoidSarcoma

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT00628628 2013-08-01

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Phase 2 Completed

82 enrolled 6 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Tumor Lysis Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hyperuricemia

Clinical Trials

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

Rasburicase in Patients at Risk for Tumor Lysis Syndrome